BACKGROUND: A theoretical advantage of preoperative therapy in pancreatic adenocarcinoma is that it facilitates the early treatment of micrometastases and reduces postoperative systemic recurrence. METHODS: Medical records of 309 consecutive patients undergoing resection of adenocarcinoma in the head of the pancreas were reviewed. Survival was calculated using the Kaplan-Meier method. Associations between preoperative therapy and patterns of recurrence were determined using chi-squared analysis. RESULTS: Preoperative therapy was administered to 108 patients and upfront surgery was performed in 201 patients. Preoperative therapy was associated with a significantly longer median disease-free survival of 14 months compared with 12 months in patients submitted to upfront surgery (P = 0.035). The rate of local disease as a component of first site of recurrence was significantly lower with preoperative therapy (11.3%) than with upfront surgery (22.9%) (P = 0.016). Preoperative therapy was associated with a lower rate of hepatic metastasis (21.7%) than upfront surgery (34.3%) (P = 0.026). Preoperative therapy did not affect rates of peritoneal or pulmonary metastasis. CONCLUSIONS: Preoperative therapy for pancreatic cancer was associated with longer disease-free survival and lower rates of local and hepatic recurrences. These data support the use of preoperative therapy to reduce systemic and local failures after resection.
BACKGROUND: A theoretical advantage of preoperative therapy in pancreatic adenocarcinoma is that it facilitates the early treatment of micrometastases and reduces postoperative systemic recurrence. METHODS: Medical records of 309 consecutive patients undergoing resection of adenocarcinoma in the head of the pancreas were reviewed. Survival was calculated using the Kaplan-Meier method. Associations between preoperative therapy and patterns of recurrence were determined using chi-squared analysis. RESULTS: Preoperative therapy was administered to 108 patients and upfront surgery was performed in 201 patients. Preoperative therapy was associated with a significantly longer median disease-free survival of 14 months compared with 12 months in patients submitted to upfront surgery (P = 0.035). The rate of local disease as a component of first site of recurrence was significantly lower with preoperative therapy (11.3%) than with upfront surgery (22.9%) (P = 0.016). Preoperative therapy was associated with a lower rate of hepatic metastasis (21.7%) than upfront surgery (34.3%) (P = 0.026). Preoperative therapy did not affect rates of peritoneal or pulmonary metastasis. CONCLUSIONS: Preoperative therapy for pancreatic cancer was associated with longer disease-free survival and lower rates of local and hepatic recurrences. These data support the use of preoperative therapy to reduce systemic and local failures after resection.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: R S Yeung; J L Weese; J P Hoffman; L J Solin; A R Paul; P F Engstrom; S Litwin; M J Kowalyshyn; B L Eisenberg Journal: Cancer Date: 1993-10-01 Impact factor: 6.860
Authors: William F Regine; Kathryn A Winter; Ross A Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Mahesh R Kudrimoti; Mitchel L Fromm; Michael G Haddock; Paul Schaefer; Christopher G Willett; Tyvin A Rich Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Sarah E Greer; J Marc Pipas; John E Sutton; Bassem I Zaki; Michael Tsapakos; Thomas A Colacchio; Jennifer J Gibson; Daniel C Wiener; Gregory H Ripple; Richard J Barth Journal: J Am Coll Surg Date: 2007-12-27 Impact factor: 6.113
Authors: Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2020-05-25 Impact factor: 5.344
Authors: Neelam V Desai; Sarunas Sliesoraitis; Steven J Hughes; Jose G Trevino; Robert A Zlotecki; Alison M Ivey; Thomas J George Journal: Cancer Med Date: 2015-03-13 Impact factor: 4.452